Medpace (NASDAQ:MEDP) Stock Price Up 0.6%

Medpace Holdings, Inc. (NASDAQ:MEDP)’s share price rose 0.6% on Thursday . The stock traded as high as $402.11 and last traded at $400.11. Approximately 52,823 shares changed hands during mid-day trading, a decline of 79% from the average daily volume of 248,554 shares. The stock had previously closed at $397.86.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research reports. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and upped their target price for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Robert W. Baird increased their price objective on Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. Deutsche Bank Aktiengesellschaft initiated coverage on Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 price objective on the stock. Finally, Guggenheim increased their price objective on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Stock Performance

The business has a fifty day moving average price of $398.32 and a 200 day moving average price of $328.94. The company has a market capitalization of $12.20 billion, a PE ratio of 40.79, a P/E/G ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million during the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue was up 17.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.27 EPS. Research analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current fiscal year.

Insider Transactions at Medpace

In related news, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the completion of the transaction, the insider now owns 5,525,959 shares in the company, valued at approximately $2,135,175,298.01. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the transaction, the chief executive officer now owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $386.39, for a total value of $5,404,823.32. Following the transaction, the insider now owns 5,525,959 shares of the company’s stock, valued at approximately $2,135,175,298.01. The disclosure for this sale can be found here. In the last quarter, insiders sold 204,442 shares of company stock worth $82,702,867. 20.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Medpace

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Medpace by 5.9% during the 4th quarter. Vanguard Group Inc. now owns 2,556,443 shares of the company’s stock valued at $783,626,000 after acquiring an additional 142,591 shares in the last quarter. Riverbridge Partners LLC raised its stake in Medpace by 7.1% during the 4th quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock valued at $199,975,000 after acquiring an additional 43,197 shares in the last quarter. Invesco Ltd. raised its stake in Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after acquiring an additional 246,775 shares in the last quarter. TD Asset Management Inc raised its stake in Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after acquiring an additional 308,816 shares in the last quarter. Finally, Wellington Management Group LLP raised its stake in Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after acquiring an additional 319,210 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.